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Abstract
Introduction Historically, the incidence rate of breast cancer
among non-Hispanic white women living in the San Francisco
Bay area (SFBA) of California has been among the highest in the
world. Substantial declines in breast cancer incidence rates
have been documented in the United States and elsewhere
during recent years. In light of these reports, we examined
recent changes in breast cancer incidence and risk factor
prevalence among non-Hispanic white women in the SFBA and
other regions of California.
Methods Annual age-adjusted breast cancer incidence and
mortality rates (1988 to 2004) were obtained from the California
Cancer Registry and analyzed using Joinpoint regression.
Population-based risk factor prevalences were calculated using
two data sources: control subjects from four case-control
studies (1989 to 1999) and the 2001 and 2003 California
Health Interview Surveys.
Results In the SFBA, incidence rates of invasive breast cancer
increased 1.3% per year (95% confidence interval [CI], 0.7% to
2.0%) in 1988–1999 and decreased 3.6% per year (95% CI,
1.6% to 5.6%) in 1999–2004. In other regions of California,
incidence rates of invasive breast cancer increased 0.8% per
year (95% CI, 0.4% to 1.1%) in 1988–2001 and decreased
4.4% per year (95% CI, 1.4% to 7.3%) in 2001–2004. In both
regions, recent (2000–2001 to 2003–2004) decreases in
invasive breast cancer occurred only in women 40 years old or
older and in women with all histologic subtypes and tumor sizes,
hormone receptor-defined types, and all stages except distant
disease. Mortality rates declined 2.2% per year (95% CI, 1.8%
to 2.6%) from 1988 to 2004 in the SFBA and the rest of
California. Use of estrogen-progestin hormone therapy
decreased significantly from 2001 to 2003 in both regions. In
2003–2004, invasive breast cancer incidence remained higher
(4.2%) in the SFBA than in the rest of California, consistent with
the higher distributions of many established risk factors,
including advanced education, nulliparity, late age at first birth,
and alcohol consumption.
Conclusion Ongoing surveillance of breast cancer occurrence
patterns in this high-risk population informs breast cancer
etiology through comparison of trends with lower-risk
populations and by highlighting the importance of examining
how broad migration patterns influence the geographic
distribution of risk factors.
Introduction
A striking feature of breast cancer epidemiology is its geo-
graphic variation in occurrence, with differences in invasive
breast cancer incidence as high as 10-fold internationally [1]
and two-fold among counties within the US [2]. At the highest
end of these spectrums are incidence rates for non-Hispanic
white women living in the San Francisco Bay area (SFBA) of
California. Recently reported rates for this population werePage 1 of 12
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have been reported to be further elevated among women in
the small SFBA county of Marin, and these findings have
received substantial public and scientific attention [3-5].
Prior studies have suggested that most [6,7], if not all [5,8],
geographic variation in US breast cancer incidence relates to
differences in the prevalence in women of established risk fac-
tors for breast cancer, including older age, non-Hispanic white
race/ethnicity, US birthplace, low- or nulli-parity, late age at
first birth, moderate to high consumption of alcohol, late age at
menopause, and use of hormone therapy (HT). Many of these
risk factors correlate with higher levels of education, income,
and other metrics of socioeconomic status, which census data
confirm to be more concentrated among SFBA residents, par-
ticularly non-Hispanic white women [9]. On this basis, it has
been hypothesized that the elevated incidence of breast can-
cer in the SFBA may be largely attributable to the high preva-
lence in women of known breast cancer risk factors as
opposed to geographically or environmentally unique features
of the SFBA. However, to date, there have been few efforts to
systematically document and compare specific risk factor
prevalences in non-Hispanic white women in the SFBA with
those in other populations [5,8].
With the recent and widely publicized changes in breast can-
cer incidence rates in this region (declines of 10% to 11%
between 2001 and 2004 [10]) and elsewhere [11-13], the
aim of this study is to determine whether incidence and mor-
tality trends are correlated with changes in the population-level
prevalence of breast cancer risk factors. In particular, HT use
dropped substantially (60% to 70%) among middle-aged
SFBA women [10] and in other populations [11,12] after the
2002 announcement by the Women's Health Initiative (WHI)
that estrogen-progestin therapy increased the risk of breast
cancer and heart disease [14]. A deeper understanding of
detailed breast cancer incidence and risk factor prevalence
patterns, particularly for distinct tumor subtypes, in this popu-
lation at the high end of the international incidence spectrum
can further inform the basis of geographic incidence variation,
especially for years after the WHI announcement, and may
offer important opportunities to generate new hypotheses
about the etiology and possible prevention of breast cancer.
With these goals in mind, we present risk factor prevalence
data and the most current breast cancer incidence rates for
the SFBA and the rest of California.
Materials and methods
Breast cancer incidence data
Breast cancer incidence and mortality data for non-Hispanic
white females were obtained from the California Cancer Reg-
istry, October 2006 submission, for the period 1 January 1988
to 31 December 2004 and for white females (Hispanics and
non-Hispanics) from the Surveillance, Epidemiology, and End
Results (SEER) program of the National Cancer Institute (NCI)
for the period 1 January 1973 to 31 December 2003 – the
most recent year for which cancer data were complete at the
time of this analysis. Analyses were based on incident cases
of breast cancer (International Classification of Diseases-
Oncology, 3rd edition [15] [ICD-O-3] site codes 50.0 to 50.9)
occurring in six counties of the SEER and California Cancer
Registry San Francisco/Oakland and San Jose/Monterey
catchment regions (Alameda, Contra Costa, Marin, San Fran-
cisco, San Mateo, and Santa Clara counties), the rest of Cali-
fornia, and the other eight original SEER regions (Connecticut,
Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta).
The populations of the six SFBA counties and the rest of Cal-
ifornia were 5,806,325 and 28,065,323, respectively. ICD-O-
3 histology codes were used to distinguish the ductal (8500)
and 'with lobular component' (8520, 8522, and 8524) histo-
logic subtypes from other subtypes of breast cancer. Stage of
disease at diagnosis was categorized as localized, regional,
distant, or unstaged/not available. Tumor size was categorized
into less than 2 cm and greater than or equal to 2 cm, and
tumor marker variables were used to define estrogen receptor
(ER) and progesterone receptor status as positive (+), nega-
tive (-), or missing. As receptor status was not reportable to
SEER until 1990, trends by receptor status are limited to the
period 1992–2004 due to higher completeness of the data
[16-20]. From 1992 to 2004, hormone receptor status was
missing for 16.9% of tumors in the SFBA and 29.2% of tumors
in the rest of California; the percentage of missing hormone
receptor status data decreased from 1992 to 1998 and was
fairly stable after that time. Although we did not impute recep-
tor status (as one prior study did [12]), the percentage of miss-
ing hormone receptor data did not vary from the period 2000–
2001 to 2003–2004.
The analyses presented in Figure 1 are based on all white
women, both Hispanic and non-Hispanic, because ethnicity
cannot be distinguished in the nine SEER regions for 1973–
2003. All other analyses reported in this paper are restricted
to non-Hispanic white women. Registry data on race/ethnicity
are based on medical record information [21]. Population
denominators were based on US Census Bureau estimates
that were 'race-bridged' (that is, persons reporting two or
more races in the 2000 census were allocated to a single race
for comparability with prior census data) [22].
Breast cancer risk factor prevalence estimates
Risk factor prevalence estimates for non-Hispanic white
women between 35 and 74 years of age were derived from
two population-based sources: (a) the California Health Inter-
view Surveys (CHISs) conducted in 2001 and 2003 (source:
2001 and 2003 CHISs) and (b) controls identified through
random digit dialing in four population-based case-control
studies conducted between 1990 and 2000 in the SFBA (risk
factor information was collected up to 1 year prior to selection
dates, 1989 to 1999). We restricted analyses to the age
group (35 to 74 years) common to the four population-basedPage 2 of 12
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Adolescent Risk Factors, which collected information up to 1
year prior to the selection dates, 1997 to 1999, from 297 con-
trols who were residents of Marin County and who did not
have a history of breast cancer [23]; (b) the San Francisco Bay
Area Breast Cancer Study, which collected information up to
1 year prior to the selection dates, 1996 to 2000, from 564
controls who were residents of Alameda, Contra Costa, San
Francisco, San Mateo, and Santa Clara counties and who did
not have a history of breast cancer [24]; (c) Reproductive Fac-
tors in Hodgkin Lymphoma (HL) in Women, which collected
information up to 1 year prior to the selection dates, 1990 to
1996, from 102 controls who were residents of Alameda,
Contra Costa, Marin, Monterey, San Benito, San Francisco,
San Mateo, Santa Clara, and Santa Cruz counties and who did
not have a history of HL at interview [25]; women with a history
of breast cancer at interview were excluded from the present
analysis; and (d) the Bay Area Thyroid Cancer Study, which
collected information up to 1 year prior to the selection dates,
1995 to 1998, from 205 controls who were residents of
Alameda, Contra Costa, Santa Clara, San Francisco, and San
Mateo counties and who did not have a history of thyroid can-
cer [26]; women with a history of breast cancer at interview
were excluded from the present analysis. Response rates in
the CHIS were 37.7% in 2001 [27] and 33.5% in 2003 [28]
and were weighted to account for under-coverage and non-
response biases [29]; response rates among controls in the
population-based case-control studies ranged from 70% to
93% [23-26].
Breast cancer risk factors included in this study have been
associated with breast cancer in prior studies [30] and either
were available in the 2001 and/or 2003 CHIS or were
assessed similarly in the four case-control studies. These fac-
tors included highest educational level attained, age at
menarche (years), age at first live birth (years), number of live
births, use of HT (ever, current, and duration in years), high
alcohol consumption (two or more drinks per day in the past
month), no vigorous or moderate physical activity in the past
30 days, and body mass index (BMI) (weight [kg]/height [m]2)
stratified by age group (less than 50 years or greater than or
equal to 50 years).
Figure 1
Trends in invasive breast cancer incidence and mortality rates among non-Hispanic and Hispanic white females in the San Francisco Bay area () and other Surveillance, Epidemiology, and E  Results (SEER) regions (o), 1973–2003
and other Surveillance, Epidemiology, and End Results (SEER) regions (o), 1973–2003.
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Cancer incidence rates
SEER*Stat software [31] was used to compute average
annual breast cancer rates age-adjusted to the 2000 US
standard million population, associated standard errors and
95% confidence intervals, and annual percent changes
(APCs). Age-adjusted rates were compared statistically using
a Wald chi-square test of the difference between two rates
[32], with p values of less than 0.05 considered significantly
different. APCs across the period 1988 to 2004 were calcu-
lated by fitting a least squares regression line to the natural
logarithm of the rates as the outcome variable, with calendar
year as the predictor variable [33]. Time trends were analyzed
using the NCI's Joinpoint software [34].
Risk factor prevalence
Prevalence estimates from the population-based controls
were age-adjusted to the 2000 US standard million population
using SAS version 9 software (SAS Institute Inc., Cary, NC,
USA). Age-adjusted prevalence estimates from the 2001 and
2003 CHISs were obtained from the internet-based AskCHIS
application. CHIS data are weighted to the California Depart-
ment of Finance estimates of the number of residents in each
California county by age, race, and gender and the 2000 Cen-
sus of Population counts from the US Census Bureau [35].
When the California and US census populations for non-His-
panic white women between 35 and 74 years of age were
compared, the distributions were found to be similar (data not
shown). The institutional review board of the Northern Califor-
nia Cancer Center approved this project.
Results
In white women (Hispanic and non-Hispanic), incidence rates
of invasive breast cancer in the SFBA have been consistently
higher than rates in other regions since the inception of con-
tinuous cancer surveillance by the SEER program in 1973
(Figure 1). The rates of both breast cancer in situ and invasive
breast cancer were higher in non-Hispanic white women in the
SFBA than in non-Hispanic white women in the rest of Califor-
nia (Figure 2). The APCs for breast cancer incidence and mor-
tality rates are presented for each time period in Table 1.
Invasive breast cancer incidence peaked in 1999 in the SFBA
and in 2001 in the rest of California before declining (Figure 2;
Table 1). Similar patterns in the incidence rate of invasive
breast cancer occurred in most disease subgroups studied,
including women 40 years old or older, all histologic subtypes,
ER+ tumors, localized and regional stage, and all tumor sizes
(Table 1). On the other hand, the incidence rate of invasive
breast cancer did not change in women under 40 years of age
and, unlike overall incidence patterns, rates of ER-, distant and
unstaged disease, and tumors of unknown size generally
decreased over the study period in both regions. For breast
cancer in situ, patterns differed, with incidence increases pla-
teauing in 1998 in the SFBA but continuing to rise in the rest
of California (Figure 2; Table 1). There were no major regional
differences in breast cancer mortality trends (Figure 3; Table
1).
From 2000–2001 to 2003–2004, rates of breast cancer in
situ and invasive breast cancer incidence significantly
decreased in the SFBA and the rest of California, as did mor-
tality rates in the non-SFBA regions of California (Table 2).
Decreases in invasive incidence rates were evident in most
subgroups, except for women under 40 years of age and dis-
tant stage of disease at diagnosis in the rest of California.
Between these two time periods, the percentage decrease in
invasive breast cancer was slightly higher in SFBA women
(12.0%) than women in the rest of California (10.9%), as were
the decreases in ER+ tumors (14.3%, SFBA; 12.9%, the rest
of California), but not tumors less than 2 cm in diameter
(11.6%, SFBA; 12.9%, the rest of California). In 2003–2004,
incidence rates of breast cancer in situ and invasive breast
cancer remained significantly higher in the SFBA than in the
rest of California by 12.5% and 4.2%. (In 2000–2001, rates
of breast cancer in situ and invasive breast cancer were
16.7% and 5.5% higher in the SFBA than in the rest of
California.)
Compared with non-Hispanic white women in the rest of Cal-
ifornia, non-Hispanic white women living in the SFBA were
more likely to have graduated from college, to have a BMI
below 25 kg/m2 (women under 50 years of age), to have been
physically active in the past 30 days, to have consumed alco-
hol in the past month (particularly two or more drinks per day),
and to have had their first child after the age of 30 years or to
be nulliparous (Table 3). From 2001 to 2003, CHIS data show
that the percentage of women who graduated from college
significantly increased in the SFBA and that the percentage of
women with less than a high school education decreased in
the rest of California. (There were no statistically significant
changes in the percentages of women with higher levels of
education in the rest of California.) Whereas there were no
changes in the prevalence of women who drank alcohol in the
past month, the prevalence of consumption of two or more
alcoholic drinks per day increased among women in the rest of
California, but not in the SFBA, between 2001 and 2003.
Based on 2001 CHIS data, significantly more women in the
SFBA than in the rest of California had undergone mammo-
graphic screening within the last 2 years. However, based on
2003 data, there were no regional differences in mammogra-
phy. To estimate combined estrogen and progestin HT use,
we examined CHIS estimates of any HT use in non-pregnant
women 40 years old or older who did not report a hysterec-
tomy [36]. Compared with women in other regions of
California, higher percentages of SFBA women used com-
bined estrogen and progestin HT in 2001. In 2003, however,
the percentages of women using combined estrogen and pro-
gestin HT were comparable in the two regions. From 2001 to
2003, CHIS data show that the percentage of women takingPage 4 of 12
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trol data from population-based case-control studies from
1989–1999 (which are not estimates of combined estrogen
and progestin HT use), the prevalence of SFBA women who
had ever used HT (44.0%) was higher than that among 2003
CHIS participants in either the SFBA (29.8%) or the rest of
California (34.5%).
Discussion
To identify new causes of breast cancer, epidemiological stud-
ies should fully characterize and, ideally, maximize the
distribution of candidate risk factors in the population under
study. With this goal in mind, we examined recent breast can-
cer incidence characteristics and trends over a 17-year period
in one of the highest-risk populations in the breast cancer lit-
Table 1
Annual percent changes in breast cancer incidence and mortality rates in non-Hispanic white women, 1988–2004.
San Francisco Bay area
Annual percent change (95% CI)
The rest of California
Annual percent change (95% CI)
Mortality rate 1988–2004: -2.20 (-2.57, -1.84) 1988–2004: -2.18 (-2.51, -1.84)
In situ incidence rate 1988–1998: +4.82 (3.82, 6.15)
1998–2004: -1.31 (-3.96, 1.41)
1988–2004: +3.94 (3.22, 4.66)
Invasive incidence rate 1988–1999: +1.32 (0.68, 1.97)
1999–2004: -3.61 (-5.61, -1.57)
1988–2001: +0.75 (0.42, 1.08)
2001–2004: -4.38 (-7.29, -1.38)
Histologic subtype
Ductal 1988–1993: -1.59 (-3.04, -0.12)
1993–1997: +4.71 (1.29, 8.24)
1997–2004: -3.29 (-4.15, -2.43)
1988–1994: -0.58 (-1.72, 0.59)
1994–1999: +1.78 (-0.41, 4.02)
1999–2004: -3.51 (-4.98, -2.02)
With lobular component 1988–1999: +5.74 (4.54, 6.95)
1999–2004: -2.26 (-5.89, 1.51)
1988–2001: +5.75 (5.30, 6.19)
2001–2004: -5.30 (-9.03, -1.42)
Age at diagnosis (years)
<40 1988–2004: +0.08 (-0.64, 0.79) 1988–2004: +0.28 (-0.25, 0.81)
40–69 1988–1999: +1.62 (0.81, 2.44)
1999–2004: -4.29 (-6.79, -1.71)
1988–2001: +0.91 (0.59, 1.23)
2001–2004: -4.14 (-7.00, -1.19)
≥70 1988–2002: +0.54 (0.04, 1.04)
2002–2004: -9.22 (-18.41, 1.02)
1988–2000: +0.68 (0.14, 1.22)
2000–2004: -4.21 (-6.93, -1.42)
ER statusa
ER+ 1992–1996: +6.85 (3.00, 10.84)
1996–2002: +0.23 (-2.34, 2.87)
2002–2004: -10.36 (-20.18, 0.67)
1992–2001: +4.53 (3.71, 5.36)
2001–2004: -7.27 (-11.18, -3.20)
ER- 1992–2004: -2.11 (-2.86, -1.35) 1992–2004: -0.56 (-1.32, 0.21)
Missing 1992–2004: -4.15 (-5.74, -2.53) 1992–2004: -4.86 (-6.40, -3.29)
Stage at diagnosis
Localized 1988–1998: +2.35 (1.60, 3.10)
1998–2004: -3.27 (-4.80, -1.72)
1988–2000: +1.36 (0.97, 1.75)
2000–2004: -3.71 (-5.67, -1.71)
Regional 1988–1993: -2.26 (-5.31, 0.89)
1993–2001: +1.96 (0.05, 3.91)
2001–2004: -7.13 (-13.48, -0.31)
1988–1996: -1.10 (-2.05, -0.14)
1996–2001: +4.06 (1.20, 7.01)
2001–2004: -6.34 (-10.38, -2.11)
Distant 1988–2004: -1.04 (-2.24, 0.17) 1988–2004: -1.17 (-1.65, -0.68)
Unstaged/Not available 1988–2004: -7.44 (-10.33, -4.46) 1988–2002: -4.24 (-5.52, -2.95)
2002–2004: -31.80 (-48.75, -9.25)
Tumor size
<2 cm 1988–1999: +3.29 (2.60,3.99)
1999–2004: -3.70 (-5.82, -1.54)
1988–2001: +2.93 (2.46, 3.41)
2001–2004: -5.88 (-9.91, -1.66)
≥2 cm 1988–1993: -1.40 (-3.51, 0.75)
1993–1998: +3.10 (0.00, 6.30)
1998–2004: -4.12 (-5.67, -2.54)
1988–1992: -2.39 (-4.59, -0.15)
1992–2001: +0.38 (-0.41, 1.17)
2001–2004: -2.91 (-6.33, 0.65)
Unknown 1988–2004: -7.28 (-8.41, -6.13) 1988–2004: -6.45 (-8.34, -4.52)
aAnnual percent change calculated for the period 1992–2004. CI, confidence interval; ER, estrogen receptor. Data from the California Cancer 
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that rates of invasive breast cancer increased from 1988 to
approximately 1999 and decreased thereafter in women 40
years old or older. From 2000–2001 to 2003–2004,
decreases in invasive breast cancer rates also occurred in
women with all histologic subtypes, tumor sizes, hormone
receptor-defined tumors, and localized and regional disease. A
recent analysis in SEER also found decreases in tumors less
than 2 cm, hormone receptor-defined tumors, and local and
regional disease from 1999/2000 to 2003 [13]. Although sim-
ilar trends were observed among non-Hispanic white women
in the rest of California in our study, incidence and mortality
rates of breast cancer were consistently higher in the SFBA
than in the rest of California or in other SEER regions across
all time periods. Even after the recent declines in 2003–2004,
incidence rates of breast cancer in situ and invasive breast
cancer were 12.5% and 4.2% higher, respectively, as com-
pared with 16.7% and 5.5% higher in 2000–2001, among
SFBA women than among women in the rest of California. Our
age-specific incidence trends are similar to recent reports of
declines in US [12,13,37,38] and German [11] women.
Contemporaneous population-based data on breast cancer
risk factors from CHIS and case-control studies provide fur-
ther evidence that in SFBA non-Hispanic white women, there
is a higher prevalence of certain breast cancer risk factors
[30], including advanced education, lower BMI among women
younger than 50 years old, nulliparity, late age at first birth, use
of estrogen plus progestin HT in 2001, and alcohol consump-
tion, as compared with non-Hispanic white women living in
other parts of California. Other breast cancer risk factors,
including use of combined estrogen and progestin HT in
2003, physical inactivity, and obesity in women 50 years old
or older, were less common in SFBA women or were similar in
SFBA women and women in the rest of California and are
therefore unlikely to have contributed to the higher incidence
rates of breast cancer in the SFBA than in the rest of
California.
The most notable risk factor changes we observed from 2001
to 2003 were the 76% and 72% relative decreases in the per-
centages of women reporting use of combined estrogen and
progestin HT in the SFBA and the rest of California, respec-
tively. Other risk factors did not appear to change substantially
Figure 2
Trends in breast cancer in situ and invasive breast cancer incidence rates among non-Hispanic white females in the San Francisco Bay area () and th  re t of California (), Califor ia C ncer R gistry, 1988–2004
the rest of California (), California Cancer Registry, 1988–2004.
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graphic screening history did increase modestly. Decreases in
HT use are comparable to those noted in our recent report of
a 68% decrease in the use of HT among middle-aged North-
ern California women after 2002 [10] and are consistent with
findings in the US [12,38] and Germany [11]. Increasing HT
use from 1994 to approximately 1999, the plateau in use from
1999 to 2001 following the 1998 release of findings from the
Heart and Estrogen/Progestin Replacement Study [39,40],
and the dramatic decrease in Northern California [10] after the
2002 WHI findings [14] closely mirror the trends we observed
in both invasive breast cancer and breast cancer in situ inci-
dence in the SFBA and the rest of California. This pattern, in
addition to the decreases in ER+ tumors, though limited by the
high percentage of missing values, further supports the notion
of a strong influence of the population prevalence of HT use
on breast cancer incidence patterns.
It is unclear to what extent mammographic screening patterns,
which have been associated with breast cancer incidence
increases in the US (particularly in the late 1980s and early
1990s [30,38,41,42]), explain the elevated incidence rates in
the SFBA. Our observations of higher incidence rates of
breast cancer in situ, detected exclusively by mammography,
and excess rates of localized and regional disease or tumors
less than 2 cm, as well as excesses in women targeted by
mammography screening guidelines (40 years old or older),
suggest that the SFBA excess could be due in part to higher
levels of screening, a finding supported by CHIS data that find
a somewhat higher prevalence of mammographic screening in
2001, but not 2003, in the SFBA. The continued assessment
of future trends in incidence rates will help us to understand
whether a plateau in mammography screening [13,38] is play-
ing a role in the observed trends.
Some, but not all [7], prior studies using ecologic and cohort
study designs have found that sociodemographic characteris-
tics [5,7] and risk factor distributions [4] explained the higher
incidence rates of breast cancer in the SFBA compared with
other regions. However, without information on residential
mobility, these studies could not address the reasons why
high-risk populations concentrate in certain geographic areas.
Demographic change in the US appears to be favoring the
migration of educated workers into certain geographic areas,
Figure 3
Trends in mortality rates among non-Hispanic white females in the San Francisco Bay area () and the rest of California (), California Cancer Reg-istry, 1988–2004
istry, 1988–2004.
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other parts of the country, and migration of service workers to
suburbs on the periphery of the educated urban cores [43].
These patterns of migration are supported by 2000 to 2004
census data that list San Francisco and San Jose among the
slowest-growing metropolitan areas and that list metropolitan
areas outside the Greater SFBA as some of the fastest-grow-
ing [44]. The extent to which these migration patterns concen-
trate women with multiple established breast cancer risk
factors in particular areas over time may help explain past and
future breast cancer incidence trends. The breast cancer inci-
dence patterns observed in SFBA women may be representa-
tive of patterns occurring in subpopulations with high breast
cancer incidence, but for whom routine surveillance is chal-
lenging, such as women residing in West Los Angeles [45],
women of high socioeconomic status [46], or female teachers
in California [47]. Cancer surveillance efforts are further lim-
ited by the lack of population counts defined by individual
characteristics, such as educational attainment within small
geographic areas, that are necessary for estimation of inci-
dence rates stratified by these characteristics. Therefore, non-
Hispanic white women in the SFBA, where surveillance is
ongoing, may serve as bellwethers for cancer trends occurring
in similar subpopulations living in more heterogeneous areas.
Table 2
Two-year average annual breast cancer incidence and mortality rates in non-Hispanic white women
San Francisco Bay area The rest of California
2000–2001
Rate (95% CI)
2003–2004
Rate (95% CI)
2000–2001
Rate (95% CI)
2003–2004
Rate (95% CI)
Mortality rate 27.4 (25.7–29.2) 26.5 (24.9–28.3) 27.8 (27.1–28.6) 25.4 (24.6–26.1)
In situ incidence rate 35.6 (33.6–37.7) 33.2 (31.3–35.2) 30.5 (29.7–31.4) 29.5 (28.7–30.4)
Invasive incidence rate 160.0 (155.9–164.3) 140.8 (136.9–144.8) 151.7 (149.9–153.6) 135.1 (133.4–136.9)
Histologic subtypea
Ductal 110.9 (107.5–114.5) 97.0 (93.7–100.3) 98.9 (97.4–100.4) 88.4 (87.0–89.8)
With lobular component 29.6 (27.8–31.5) 26.9 (25.2–28.7) 30.4 (29.6–31.2) 27.0 (26.2–27.8)
Age at diagnosis (years)a
<40 13.1 (11.5–15.0) 14.0 (12.1–16.1) 13.0 (12.2–13.9) 13.0 (12.2–13.9)
40–69 305.5 (295.4–315.8) 263.1 (253.9–272.5) 287.3 (282.8–291.9) 255.5 (251.3–259.7)
≥70 535.3 (511.7–559.8) 475.7 (452.4–499.9) 511.6 (501.3–522.0) 447.8 (438.0–457.7)
ER/PR statusa
ER+/PR+ 96.0 (92.7–99.3) 83.7 (80.7–86.8) 76.0 (74.7–77.3) 65.9 (64.7–67.2)
ER+/PR- 19.5 (18.0–21.0) 15.3 (14.1–16.7) 15.9 (15.3–16.5) 14.1 (13.5–14.6)
ER-/PR+ 2.3 (1.8–2.9) 1.0 (0.7–1.4) 1.9 (1.7–2.1) 1.3 (1.1–1.5)
ER-/PR- 21.6 (20.1–23.3) 20.3 (18.8–21.9) 20.5 (19.8–21.3) 19.6 (18.9–20.2)
Missing 20.7 (19.3–22.3) 20.3 (18.9–21.9) 37.4 (36.5–38.4) 34.3 (33.4–35.1)
Stage at diagnosisa
Localized 103.4 (100.1–106.8) 93.1 (89.9–96.4) 95.0 (93.5–96.5) 84.6 (83.3–86.0)
Regional 48.4 (46.1–50.8) 40.5 (38.4–42.7) 47.8 (46.8–48.9) 42.0 (41.0–43.0)
Distant 6.0 (5.2–6.9) 5.3 (4.5–6.1) 5.4 (5.0–5.8) 5.5 (5.2–5.9)
Unstaged/Not available 2.3 (1.8–2.8) 1.5 (1.1–1.9) 3.4 (3.2–3.7) 2.2 (2.0–2.5)
Tumor size
<2 cm 93.4 (90.2–96.7) 82.6 (79.6–85.7) 84.8 (83.4–86.2) 73.9 (72.6–75.2)
≥2 cm 58.1 (55.6–60.7) 51.6 (49.2–54.1) 58.2 (57.0–59.4) 53.5 (52.4–54.6)
Unknown 8.5 (7.6–9.5) 6.1 (5.3–6.9) 8.8 (8.3–9.2) 7.1 (6.7–7.5)
All rates per 100,000 and age-adjusted to the 2000 US age standard. aInvasive breast cancer. CI, confidence interval; ER, estrogen receptor. 
Data from the California Cancer Registry.Page 8 of 12
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Prevalence of breast cancer risk factors in non-Hispanic white women 35 to 74 years of age
Patient characteristics Population-based 
control series 
(1989–1999)
California Health Interview Survey
SFBA
(n = 1,168)
2001 2003
SFBA Californiaa SFBA Californiaa
Education
Some high school or less 3.2 (2.2–4.2) 2.3 (1.2–3.3) 7.5 (6.7–8.3) 2.9 (1.5–4.4) 6.2 (5.4–7.0)
High school graduate 20.7 (17.9–23.4) 18.1 (16.0–20.2) 23.3 (22.4–24.3) 15.4 (13.3–17.5) 23.8 (22.6–25.0)
Some college 27.7 (24.5–30.9) 27.0 (24.6–29.3) 34.4 (33.3–35.5) 25.1 (22.6–27.7) 34.3 (33.1–35.6)
College graduate or higher 46.7 (42.5–50.9) 52.7 (50.0–55.3) 34.8 (33.7–35.9) 56.5 (53.6–59.4) 35.6 (34.3–36.9)
Missing 1.6
Body mass index <25 in women <50 years 64.4 (56.6–72.1) 64.1 (60.4–67.7) 58.0 (56.2–59.7) 63.9 (59.7–68.1) 57.2 (55.1–59.3)
Body mass index ≥ 30 in women ≥ 50 years 20.9 (17.5–24.2) 21.7 (18.5–24.8) 21.5 (20.2–22.9) 21.1 (17.7–24.5) 22.9 (21.4–24.4)
History of breast cancer in mother, sister, or 
daughter
13.9 (11.6–16.1) b b b b
Ever had a breast biopsy that was not cancer 11.7 (9.8–13.5) b b b b
Ever had radiation treatment to the chest 2.0 (1.2–2.7) b b b b
No vigorous/moderate physical activity in past 
30 days
b 19.8 (17.7–22.0) 23.4 (22.4–24.4) b b
Drank alcohol in past month b 71.3 (68.9–73.8) 61.3 (60.1–62.4) 69.8 (67.0–72.7) 61.0 (59.7–62.3)
2+ drinks per dayc 27.6 23.6 28.0 25.9
Age at menarche <12 years 21.0 (18.2–23.8) 18.5 (16.4–20.6) 19.4 (18.5–20.4) b bPage 9 of 12
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Breast Cancer Research    Vol 9 No 5    Keegan et al.Age at first live birth ≥ 30 years 20.7 (17.8–23.7) 20.4 (18.3–22.5) 13.4 (12.6–14.2) b b
Number of live births
0 25.0 (21.9–28.1) 25.3 (23.2–27.4) 17.3 (16.5–18.2) b b
1–2 48.2 (43.9–52.6) 51.4 (48.7–54.0) 48.0 (46.8–49.2)
≥3 26.7 (23.8–29.7) 23.3 (21.0–25.6) 34.7 (33.6–35.8)
Hormone therapy use
Never 53.7 (48.8–58.5) b b b b
<5 years 21.2 (18.6–23.8)
≥5 years 22.8 (20.3–25.3)
Missing 2.3
Ever took hormone supplements for 
menopause symptoms
b b b 29.8 (26.7–33.0) 34.5 (32.9–36.0)
Currently takes hormone supplements for 
menopause symptoms
b 34.9 (32.1–37.7) 37.0 (35.8–38.2) 16.7 (14.2–19.1) 21.6 (20.4–22.7)
Among women without a hysterectomyd 20.4 18.7 4.9 5.2
Mammogram screening history
2 years or less b 72.9 (70.5–75.2) 70.4 (69.3–71.5) 71.0 (68.3–73.7) 71.6 (70.3–72.8)
More than 2 years ago 12.1 (10.4–13.8) 13.7 (12.9–14.5) 12.9 (10.9–14.9) 13.4 (12.5–14.3)
Never had a mammogram 15.1 (13.1–17.0) 15.9 (15.0–16.8) 16.1 (13.8–18.3) 15.0 (14.0–16.1)
aExcluding the SFBA. bNot available in the population-based control series or AskCHIS. cCalculated by dividing the number of women drinking 2+ 
drinks per day in the past 30 days by the total number of women (that is, the number of women who did and did not drink alcohol in the past 30 
days). dCalculated by dividing the number of women who did not have a hysterectomy and reported using hormone supplements by the total 
number of women (that is, the number of women who did and did not take hormone supplements for menopause symptoms). SFBA, San 
Francisco Bay area.
Table 3 (Continued)
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is, the data are available only at a geographic (that is, county)
level rather than at the individual level. In addition, we did not
adjust breast cancer incidence rates for known risk factors,
nor did we have population prevalence estimates of risk factor
changes over the 17-year study period or in the rest of the
SEER regions. We were able to present risk factor changes
between variables measured similarly in the 2001 and 2003
CHISs, but these data are limited by low response rates that
could result in selection bias. However, response rates in
CHIS were comparable to those in other population-based
surveys [29], and response rates among the population-based
controls included in the present analysis, though not directly
comparable to CHIS, were higher. Even with these limitations,
the ability to examine the prevalence of established breast can-
cer risk factors from two population-based sources allowed us
to compare the prevalence of breast cancer risk factors in
SFBA non-Hispanic white women with similar women in the
rest of California. Furthermore, our data provided sufficient
power for examining incidence trends by age, histologic sub-
type, stage at diagnosis, and hormone receptor status.
Conclusion
Understanding breast cancer incidence and risk factor preva-
lence patterns in SFBA non-Hispanic white women informs
the study of breast cancer etiology in two ways. First, future
population-based studies attentive to exposure heterogeneity
might include SFBA counties together with other US or inter-
national populations with lower documented incidence rates
of breast cancer, in which established or putative risk factors
may be less common, and protective factors may be more
common. Second, high-incidence populations are also useful
for the study of potentially important, yet poorly studied, com-
munity-level or cultural influences on breast cancer occur-
rence. A Wisconsin study [48], for instance, found that breast
cancer risk was associated with high community socioeco-
nomic status after adjustment for individual-level education
and other established risk factors, suggesting that living in
affluent communities impacts breast cancer risk above and
beyond the risk conferred by individual risk factors. Thus, doc-
umenting breast cancer occurrence patterns in high-incidence
regions, such as the SFBA, continues to be an activity of
importance to breast cancer prevention efforts.
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